{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:54:56Z","timestamp":1784829296356,"version":"3.55.0"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T00:00:00Z","timestamp":1494979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with myelofibrosis at intermediate\u20101 risk according to the International Prognostic Score System are projected to a relatively long survival; nonetheless, they may carry significant splenomegaly and\/or systemic constitutional symptoms that hamper quality of life and require treatment. Since registrative COMFORT studies included only patients at intermediate\u20102\/high International Prognostic Score System risk, safety and efficacy data in intermediate\u20101 patients are limited. We report on 70 intermediate\u20101 patients treated with ruxolitinib according to standard clinical practice that were evaluated for response using the 2013 IWG\u2010MRT criteria. At 6\u00a0months, rates of spleen and symptoms response were 54.7% and 80% in 64 and 65 evaluable patients, respectively. At 3\u00a0months, ruxolitinib\u2010induced grade 3 anemia and thrombocytopenia occurred in 40.6% and 2.9% of evaluable patients, respectively. Notably, 11 (15.9%) patients experienced at least one infectious event \u2265grade 2. Most (82.6%) patients were still on therapy after a median follow\u2010up of 27\u00a0months. These data support the need for standardized guidelines that may guide the decision to initiate ruxolitinib therapy in this risk category, balancing benefit expectations and potential adverse effects.<\/jats:p>","DOI":"10.1002\/hon.2429","type":"journal-article","created":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T06:13:27Z","timestamp":1495001607000},"page":"285-290","source":"Crossref","is-referenced-by-count":45,"title":["Efficacy and safety of ruxolitinib in intermediate\u20101 IPSS risk myelofibrosis patients: Results from an independent study"],"prefix":"10.1002","volume":"36","author":[{"given":"Francesca","family":"Palandri","sequence":"first","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L. and A. Ser\u00e0gnoli' University of Bologna, S. Orsola\u2010Malpighi Hospital  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Tiribelli","sequence":"additional","affiliation":[{"name":"Division of Hematology and Stem Cell Transplantation Azienda Sanitaria Universitaria Integrata  Udine Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Benevolo","sequence":"additional","affiliation":[{"name":"Division of Hematology Citt\u00e0 della Salute e della Scienza Hospital  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Tieghi","sequence":"additional","affiliation":[{"name":"Department of Hematology A.O. Arcispedale Santa Maria Nuova \u2013 IRCCS  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cavazzini","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Ferrara  Ferrara Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[{"name":"Division of Cellular Biotechnologies and Hematology University Sapienza  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Bergamaschi","sequence":"additional","affiliation":[{"name":"Division of Hematology IRCCS AOU San Martino\u2010IST  Genoa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Sgherza","sequence":"additional","affiliation":[{"name":"Division of Hematology Casa Sollievo Sofferenza  San Giovanni Rotondo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Polverelli","sequence":"additional","affiliation":[{"name":"Unit of Blood Diseases and Stem Cell Transplantation ASST Spedali Civili di Brescia  Brescia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Crugnola","sequence":"additional","affiliation":[{"name":"Division of Hematology AOU of Parma  Parma Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Isidori","sequence":"additional","affiliation":[{"name":"Hematology and Stem Cell Transplant Center AORMN Hospital  Pesaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Binotto","sequence":"additional","affiliation":[{"name":"Hematology and Clinical Immunology Unit University of Padova  Padova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[{"name":"Innere Medizin II, H\u00e4matologie und Onkologie Universit\u00e4tsklinikum Jena  Jena Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Buccisano","sequence":"additional","affiliation":[{"name":"Division of Hematology Policlinico Tor Vergata  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Martino","sequence":"additional","affiliation":[{"name":"Division of Hematology Azienda Ospedaliera 'Bianchi Melacrino Morelli'  Reggio Calabria Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Latagliata","sequence":"additional","affiliation":[{"name":"Division of Cellular Biotechnologies and Hematology University Sapienza  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5098-3901","authenticated-orcid":false,"given":"Marco","family":"Spinsanti","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L. and A. Ser\u00e0gnoli' University of Bologna, S. Orsola\u2010Malpighi Hospital  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Kallenberg","sequence":"additional","affiliation":[{"name":"Innere Medizin II, H\u00e4matologie und Onkologie Universit\u00e4tsklinikum Jena  Jena Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Alberto","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Division of Hematology AOU 'Policlinico\u2010V.Emanuele'  Catania Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Abruzzese","sequence":"additional","affiliation":[{"name":"Division of Hematology Ospedale S. Eugenio  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Scaffidi","sequence":"additional","affiliation":[{"name":"Department of Hematology University of Verona  Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cuneo","sequence":"additional","affiliation":[{"name":"Division of Hematology University of Ferrara  Ferrara Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L. and A. Ser\u00e0gnoli' University of Bologna, S. Orsola\u2010Malpighi Hospital  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Vianelli","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L. and A. Ser\u00e0gnoli' University of Bologna, S. Orsola\u2010Malpighi Hospital  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Bonifacio","sequence":"additional","affiliation":[{"name":"Department of Hematology University of Verona  Verona Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09179.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-293415"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"issue":"21","key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood.V124.21.405.405","article-title":"Mutation\u2010enhanced International Prognostic Scoring System (MIPSS) for primary myelofibrosis: an AGIMM & IWG\u2010MRT project","volume":"124","author":"Vannucchi AM","year":"2014","journal-title":"Blood"},{"key":"e_1_2_8_7_1","volume-title":"JAKAVI: Summary of Product Characteristics","author":"European Medicines Agency","year":"2014"},{"key":"e_1_2_8_8_1","volume-title":"Jakafi (Ruxolitinib) Tablets [Prescribing Information]","author":"Incyte Corporation","year":"2014"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.143677"},{"key":"e_1_2_8_12_1","first-page":"1","article-title":"Ruxolitinib \u2010 better prognostic impact in low\u2010intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis","author":"Mazza P","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00277-016-2884-7","article-title":"Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph\u2010negative MPN","volume":"96","author":"Breccia M","year":"2017","journal-title":"Ann Hematol"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-488098"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404914"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"issue":"2","key":"e_1_2_8_18_1","first-page":"51S","article-title":"Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults\u2014the evidence report. National Institutes of Health","volume":"6","year":"1998","journal-title":"Obes Res"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13379"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-414631"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","unstructured":"MarchettiM BarosiG CervantesF et al.Which patients with myelofibrosis should receive ruxolitinib therapy?ELN\u2010SIE evidence\u2010based recommendations. Leukemia.2016.","DOI":"10.1038\/leu.2016.283"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2012.12.018"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-531103"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24572"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485888"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119545"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2429","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T10:54:33Z","timestamp":1695552873000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,17]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1002\/hon.2429"],"URL":"https:\/\/doi.org\/10.1002\/hon.2429","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,17]]}}}